Novartis reports strong double-digit growth in sales and income

| Source: Novartis Pharma AG Novartis Pharma AG

Novartis reports strong double-digit growth in sales and income, gaining market share in first half of 2004

Operating income expands faster than sales

Key figures

  • First-half Group sales reach USD 13.6 billion, up 14% (+9% lc), fueled by Pharmaceuticals growth of 17% (+11% lc) and Consumer Health increase of 9% (+4% lc)

  • Double-digit Pharmaceutical sales expansion driven by top primary care brands Diovan, Lotrel, Lamisil and Trileptal as well as specialty medicine products Gleevec/Glivec, Zometa, Femara and Visudyne

  • Consumer Health driven by solid OTC, Medical Nutrition and CIBA Vision performance

  • Operating income expands faster than sales, reaching USD 3.3 billion, as operating margin increases 0.6 percentage points due to excellent business performance and effective resource allocation

  • Net income surges 19% to USD 2.8 billion as EPS expands 21%

    • Attachments

    Media release (PDF)